Purdue Pharma LP next week will present a new formulation of its painkiller OxyContin to a panel of outside advisers to the FDA, as it competes with other companies to introduce tamper-resistant drugs that addicts cannot abuse. Alpharma, Pain Therapeutics and Elite Pharmaceuticals are working on alternative treatments to capture a share of a market that could be worth $1 billion.

Full Story:

Related Summaries